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Environmental agents such as radiation and chemicals are known to cause genetic damage. Alterations
in a limited set of cellular genes called proto-oncogenes lead to unregulated proliferation and differen-
tiation. We have studied the role of the ras gene family in carcinogenesis using two different animal
models. In one case, thymic lymphomas were induced in mice by either gamma or neutron radiation, and
in the other, keratoacanthomas were induced in rabbit skin with dimethylbezanthracene. Human kera-
toacanthomas similar to the ones induced in rabbits were also analyzed. We found that different types of
radiation such as gamma rays and neutrons, induced different point mutations in ras genes. A novel K-
ras mutation in codon 146 has been found in thymic lymphomas induced by neutrons. Keratoacanthomas
induced in rabbit skin bydimethylbenzanthracene show ahigh frequencyofH-ras-activated genescarrying
a mutation in codon 61. The same is observed in human keratoacanthomas, although mutations are in
both the 12th and the 61st codons ofthe H-ras gene. H-ras activation is less frequent in human squamous
cell carcinomas than in keratoacanthomas, suggesting that ras genes could play a role in vivo in differ-
entiation as well as in proliferation.
Introduction
Cell growth is a carefully regulated process that re-
sponds to specific needs of organismic development.
However, occasionally, the sophisticated mechanisms of
control that regulate cell multiplication break down and
a cell begins to proliferate, giving rise to a tumorous
growth. Both benign and malignant tumors represent
abnormal cell growth, although they are completely dif-
ferent in terms of their properties of invasiveness and
spread.
Changes in the DNA of somatic cells are the genetic
events that transform a normallyregulated cell into one
that grows without responding to controls. These
changes have beenrecently assigned to a group ofgenes
called proto-oncogenes. When they are activated these
genes are called oncogenes, whose products cause the
inappropriate cell growth. One group ofsuch oncogenes
constitutes the ras gene family. Members of the ras
gene family (H-, K-, and N-ras) are mutated in ap-
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proximately 20% of all human tumors, making them
themostcommonlyactivatedoncogenes(1,2). rasGenes
codeforsimilarproteins ofmolecularweight21,000(188
amino acids). There is a striking correlation between
the tissue type affected in experimental tumors and the
typeofrasgeneactivated. Allepithelial-derived tumors
(skin, breast, liver) have H-ras activated, while mes-
enchymal tumors (lymphomas, fibrosarcomas, renal
mesenchymal) have either K-ras or N-ras activated(3-
5).
Activation ofras oncogenes has been shown to occur
via point mutations in alimited number ofcodons (most
frequently codons 12, 13, and 61). These codons are
believed to code for amino acids that are important for
p21 activity. ras Genes activated by somatic mutations
in vivo have been most frequently detected in codons
12 or 61 (6).
In this report we outline the result obtained on ras
activation in tumors different in a) species (mouse, rab-
bit, human), b) type of tumor (lymphomas, keratocan-
thomas), c) inducingagent (radiations, chemicals, spon-
taneous), and d) tumor agressivity (malignant and
benign). Different members of the ras gene family are
reproducibly activated in the different tumors. Molec-
ular analysis in these models indicates that ras activa-
tion interferes both with cell proliferation and differ-
entiation, but other genetic changes are necessary for
tumor development.COROMINAS ET AL.
Methods to Detect ras Mutations
We have used two assays that can demonstrate the
existence of activated ras oncogenes in tumors and
which demonstrate that transforming activity is asso-
ciated with the genes. These methods, the nude mouse
assay and focus-forming assay, take advantage of the
factthat activated ras genes "transform" NIH3T3cells;
that is, the cells lose the property of contact inhibition
and acquire a rounded morphology. In these assays,
tumor DNA is transfected into NIH 3T3 cells. In the
focus-forming assay, the cells are cultured in 5% calf
serum. Under these conditions, ras-transformed cells
have a growth advantage over normal cells and form
"foci" ofphenotypically transformed cells overthe mon-
olayer ofnormal cells. In the nude mouse assay, tumor
DNA is co-transfected with a G418-resistance gene as
a dominant, selectable biochemical marker. Cells that
take up the foreign DNA will survive in the presence
of the antibiotic G418. After 2 weeks, cells are inocu-
latedintonudemice. Tumorformationisassociatedwith
the presence of transforming DNA sequences in the
injected cells (7). Molecular analysis of foci DNA and
nude mouse tumor DNA is then used to determine the
oncogene (ras or non-ras) that is present. The trans-
forming sequences are detected by Southern blot analy-
sis.
Two methods were used to identify point mutations
in ras genes in primary or nude mouse tumors. Prior
to assaying for a ras mutation, the exon containing the
possible ras mutation was amplified by the polymerase
chain reaction (PCR) (8-10). In the first assay, the am-
plified samples were then affixed to nylon membranes
using a slot blot apparatus, and the membranes were
hybridized to 32P-labeled oligonucleotides specific for
the relevant point mutations. The membranes were
washed inconditions inwhich nolabeled proberemained
bound to slots containing PCR-amplified normal brain
DNA. In the second assay, the amplified DNA frag-
ments were sequenced using a modification ofthe San-
ger dideoxy chain terminator method (11,12).
Comparison between Different
Forms of Ionizing Radiation
Interaction of Ionizing Radiation with
Cells and Molecules
Among the environmental agents that are potentially
carcinogenic are different forms of ionizing radiation.
Ionizing radiation can be classified as being particulate
or electromagnetic or as being densely or sparsely ion-
izing. We have compared the carcinogenic effects of
gamma radiation, a sparsely ionizing electromagnetic
radiation, with neutrons, a densely ionizing particulate
radiation. Because of the different properties of these
types of radiation, they deliver energy to intracellular
target molecules in different ways (13). Neutrons di-
rectly interactwithintranucleartargetmolecules, while
gamma rays transfer energy to orbital electrons of sev-
eralintracellularmolecules, mainlywater, creatingfree
radicals that chemically react with DNA.
Both neutron and gamma irradiation are potential
carcinogens, as demonstrated by the fact that both can
transform cells in vitro (14-16) and induce tumors, in-
cludingthymic lymphomas, in animals (17,18). One goal
ofthis study was to determine whether the differences
in qualities of these different forms of radiation might
result in tumors with a different pattern of ras gene
mutations. To that aim, we induced tumors with neu-
trons and compared the results with previous data ob-
tained from tumors induced by gamma radiation.
Induction of Mouse Thymic Lymphomas
with Neutrons
An optimal dose of neutron radiation for efficiently
inducing thymic lymphomas in female RF/J mice (age
4-7weeks) was determined bytestingseveral different
doses (0.8, 1.0, 2.0, and 3.0 Gy) of 0.44 MeV neutrons
administered at onetime as whole bodyirradiation. The
most effective dose was 1.0 Gy, with 71% of 34 mice
that received this dose developing thymic lymphomas
(mean latency of induction of 170 + 23 days). A dose
of2.0or3.0Gyofneutronsresultedinradiationsickness
and early death, and only 1 of 7 (14%) of mice that
received 0.8 Gy of neutrons developed a thymic lym-
phoma.
Activating ras Mutations Detected in
Neutron-Induced Thymic Lymphomas
Two assays, the nude mouse assay and differential
oligonucleotide hybridization to PCR-amplified DNA,
were independently used to detect activated ras genes
in the neutron-induced thymic lymphomas (8,19,20).
Both assays were used because the nude mouse assay
detects the transforming activity of a gene, while dif-
ferential oligonucleotide hybridization detects specific
mutations in the gene.
A total of six neutron-induced thymic lymphomas
scored positive in the nude mouse assay. Southern blot
analysis ofnudemousetumorDNAshowedthatofthese
sixthymic lymphomas which scored positive inthe nude
mouse assay, three contained an activated K-ras gene,
one contained an activated N-ras gene, and two did not
contain an actived H-, K-, or N-ras gene.
The second assay, differential oligonucleotide hybrid-
ization to PCR-amplified DNA, only detects the specific
mutations that the oligonucleotide probes are designed
to detect. The first two exons of K- and N-ras were
separately amplified by PCR in each ofthe thymic lym-
phomas using primers that have been described else-
where (10). We decided to screen these tumors for all
possible missense mutations in codons 12, 13, and 61
since these are the locations where most activating ras
mutations and all activating ras mutations in murine
thymic lymphomas have been detected (6,21,22). Ofthe
24 thymic lymphomas screened in this assay, 3 were
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shown to contain a mutated ras gene. No two tumors
contained the same mutation. Two of the mutations
were in codon 12 of K-ras (GGT to TGT and GGT to
GTT), and the other mutation was in codon 61 ofN-ras
(CAA to AAA) (Fig. 1). These three thymic lymphomas
had scored positive in the nude mouse assay. Differ-
ential oligonucleotide hybridization to PCR-amplified
DNA confirmed that each nude mouse tumor derived
from athymic lymphoma containing a ras mutation con-
tained the same ras mutation as the thymic lymphoma
from which it was derived.
One neutron-induced lymphoma and the three nude
mouse tumors derived from it that contained an acti-
vated K-ras gene did not contain any of the mutations
screened for by differential oligonucleotide hybridiza-
tion. In order to determine the mutation responsible for
activating this K-ras gene, each ofthe five coding exons
ofK-ras (1,2,3,4A, and 4B) from one ofthe nude mouse
tumors was sequenced after PCR amplification. The
only mutation detected, an ACA-for-GCA substitution,
was located in codon 146. This mutation, which results
in the substitution of the amino acid threonine for the
normal alanine, has not been detected in any other sys-
tem. Differential hybridization of oligonucleotides to
PCR-amplified DNA confirmed that the mutation in co-
don 146 was present in the thymic lymphoma (Fig. 1).
Comparison between Neutron and Gamma
Radiation in ras Mutation Induction
To determine the frequency ofthe codon 146mutation
in thymic lymphomas induced by gamma radiation and
neutron radiation, we screened DNA samples from the
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FIGURE 1. Slot blots of neutron-induced tumor DNA hybridized to
oligonucleotide probes specific for single point mutations. Each
panel consists of eight slots containing neutron-induced tumor
DNA and one slot containing normal RF strain mouse brain DNA.
In each panel, a different tumor is positive for the indicated mu-
tation. Normal brain DNA samples are located in slots 3c ofpanels
1 and 4 and 3A of panels 2 and 3.
24 neutron-induced thymic lymphomas and from 25
gamma-radiation-induced thymic lymphomas forthe co-
don 146 mutation using differential oligonucleotide hy-
bridization. All tumors had been induced in RF/J mice
and had been previously screened for mutations in co-
dons 12, 13, and 61 ofK- and N-ras (21). None ofthese
thymic lymphomas contained a point mutuation in the
first base of codon 146.
Unlike gamma radiation, which preferably induces
oneparticularpointmutation, neutronradiationinduces
a variety ofras point mutations (Table 1). In a previous
report from our laboratory, 24% (9 of 37) of gamma
radiation-induced thymic lymphomas contained an ac-
tivatedras gene (21). Eighty-ninepercent ofthetumors
(8 of 9) contained an activated K-ras, and 87.5% (7 of
8) of these had a GGT to GAT point mutation in codon
12 of K-ras (21). In comparison to gamma-ray-induced
tumors, a smallerproportion ofneutron-induced tumors
contained an activated ras gene (17% versus 24%). The
spectra of ras mutations induced by the two forms of
radiation were also different. Unlike gamma radiation,
neutrons have not lead to a preponderance of any one
particular mutation and have not induced any tumors
with a GAT for GGT substitution in K-ras codon 12, the
most common mutation detected in gamma-ray-induced
tumors. This difference in ras mutation spectra was
found to be statistically significant.
Several hypotheses could explain the different spec-
tra of ras mutations induced by different forms of ra-
diation. Biological selection alone cannot explain the
preponderance of one mutation induced by gamma ra-
diation since many othermutations, some ofwhich have
been induced by neutrons radiation, are biologically ac-
tive.
DNA conformation and DNA-protein interactions
could make the second base of codon 12 susceptible to
the effects ofgamma radiation. Gamma radiation dam-
ages DNAindirectlythroughthe production offreerad-
icals (23), and the conformation of DNA and DNA-pro-
teininteractions could affectthedamage createdbyfree
radicals (24).
Relative inefficiency in repairing a gamma-radiation-
induced lesion at one particular base might account for
the high frequency of a gamma-radiation-induced mu-
tation at that site. While it is known that the effective-
Table 1. Comparison between activating mutations in neutron-
and gamma-radiation-induced tumors.
Activating mutations Gamma raysa Neutrons
K12GGT GAT 7 (19%) 0
K12 GGT - TGT 1 (4%)
K12 GGT - GTT 1 (4%)
K146 GCA -* ACA 1 (4%)
N61 CAA AAA 1 (4%)
N12 GGT GAT 1 (3%) 0
Total tumors 37 24
Total tumors with an 9 (24%) 4 (17%)
activated ras gene
aThe activatingmutation was not determined inonetumorcontaining
an activated K-ras gene. These results are summarized from Sloan et
al. (10) and Diamond et al. (21).
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ness of the UvrABC excision repair system of Esche-
richia coliis affected bythe nucleotides nearadamaged
base (25) and that DNA damage produced by gamma
radiation is often repaired in mammalian cells (23), it is
unknown whether mammalian repair enzymes are af-
fected bythe DNAsequence nearadamagedbase. Neu-
tron-induced damage may be more difficult to repair
because neutrons are thought to produce dense clusters
oflesions in DNA molecules (26).
Alternatively, neutrons may induce DNA damage
that is qualitatively different from gamma-ray-induced
lesions, and these neutron-induced lesions may be in-
efficiently repaired by cellular repair enzymes. Diffi-
culty in repairing neutron-induced DNA lesions re-
gardless of the location of the lesion could result in a
variety of mutations in neutron-induced tumors.
Biological Activity of ras Mutated at
Codon 146
To verify that the novel form of K-ras mutated in
codon 146 is an active oncogene, we tested this gene in
the NIH 3T3 focus-forming assay. Nude mouse tumor
DNA samples were used in the focus-forming assay,
and normal thymus DNA was used as the negative con-
trol. While the K-ras gene mutated in codon 146 was
active in the focus-forming assay, it was less efficient
than K-ras activated by a GAT for GGT substitution in
codon 12 or by a GAT for GGT substitution in codon 13
(0.9 foci/,ug versus 0.29 foci/,ug versus 0.18 foci/,ug, re-
spectively). These differences were not due to differ-
ences in the number of copies ofactivated K-ras, since
densitometric analysis of Southern blots showed that
the nude mouse tumor containing the K-ras codon 146
mutated gene contained more copies of integrated K-
ras than did the other tumors used in the focus-forming
assay.
In comparison to the activity of other mutations in
the NIH 3T3 focus-forming assay, the reduced activity
ofthe ras gene mutated in codon 146 suggests that this
gene has weaker transforming activity than do other
activating mutations. The latencies of the nude mouse
tumors induced by ras genes activated by different mu-
tations also suggest thatthe codon 146mutation confers
less transforming activity on the ras gene than do other
mutations. The latency ofthe nude mouse tumors con-
taining the K-ras gene mutated at codon 146 was 21.7
+ 3.5 days; the latency of the ras genes mutated in
codons 12 or 61 were 16.5 + 1.6 days. This difference
was statistically significant. Inagreementwith ourfind-
ings, a recent report showed that an in vitro mutagen-
ized H-ras gene with a mutation in codon 146 had less
transforming activity than did a ras gene with a codon
12 mutation (27).
A Ser-Ala-Lys consensus sequence at codons 145 to
147 ofthe N-, K-, and H-ras genes ofmammals and in
the ras genes of several other eukaryotes (6) implies
that this region has functionalimportance. X-rayanaly-
sis of crystallized p21 predicts that this region of the
molecule interacts with the purine component of GTP
and GDP (28,29). Furthermore, increased guanine nu-
cleotide exchange rates have been measured in the pro-
tein encoded by an H-ras gene mutated at codon 146 by
in vitro mutagenesis (27).
ras Activation in Chemically
Induced Rabbit Keratoacanthomas
Skin carcinogenesis is a convenient model because
tumor development can be easily monitored. We took
advantage ofthis by inducing keratoacanthomas in rab-
bit skin with the cyclic hydrocarbon dimethylbenzan-
thracene (DMBA). Keratoacanthomas are benign tu-
mors that can be induced by repeated applications of
DMBA on the internal face of rabbit ears and sponta-
neously regress (30,31). Therefore, keratoacanthomas
offer a unique model for the identification ofoncogenes
that are not sufficient to maintain tumorgrowth. DNAs
from different tumors were transfected into NIH 3T3
cells and tested for the presence oftransforming genes
in the focus-forming assay, as described above. About
60% (10outof17) scoredpositiveinthisassay. Southern
blothybridizations with aratH-rasprobedemonstrated
that all of the transformants contained extra copies of
the rabbit H-ras gene (Fig. 2).
The transforming p21 present in keratoacanthoma
transformants was detected by immunoprecipitation
with the monoclonal antibody Y13-259, which detects
ras proteins from different species (32). The transform-
ing H-ras protein had a faster electrophoretic mobility
than the normal protein (Fig. 3). This suggested that
the activating mutation was in codon 61 because mu-
tations in this codon give rise to faster forms of p21,
FIGURE 2. Identification of H-ras as the transforming oncogene of
rabbitkeratoacanthomas. DNAs fromthecorresponding NIH3T3
transformants were digested with EcoRI and analyzed by South-
ern blot using the rat v-H-ras gene as a probe (BS9). The arrow
indicates the extra band of the transformant used to clone the
gene.
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FIGURE 3. Immunoprecipitation of ras proteins from rabbit kera-
toacanthoma transformants. The cells were labeled with 35S-Met,
lysed, and immunoprecipitated with a monoclonal antibody. The
samples are: two NIH 3T3 transformants from two rabbit kera-
toacanthomas (A,B), rabbit fibroblasts R9ab (C), NIH 3T3 (D),
human fibroblasts (E), and NIH 3T3 transformed with H-ras mu-
tated in codon 12 (T24 transformant) (F).
whereas mutations in codon 12 generate proteins with
aslightly decreased mobilityinpolyacrilamide gels (33).
To identify the mutation responsible for H-ras acti-
vation inrabbit keratoacanthomas, we cloned the trans-
forming gene from a transformant. The sequence ofthe
second exon ofthe gene revealed a mutation in the 61st
codon ofthe protein. This is an A:T to T:A transversion
that changes the codon from CAG (Gln) to CTG (Leu).
The mutations present in the other rabbit keratoacan-
thomas were analyzed bypolymerase chainreaction am-
plification and oligonucleotide mismatch hybridization
(34). This technique revealed that 90% of the keratoa-
canthomas contained the samemutationincodon61 (35).
Other types of tumor induced by DMBA contained ac-
tivated ras genes with mutations in codon 61. This in-
cludes mouse skin carcinomas (4) and papillomas (36)
and rat mammary tumors (37). The reason for this pref-
erential mutation in codon 61 by DMBA might be due
to carcinogen specificity. The findingofH-ras activation
in tumors that spontaneously regress such as keratoa-
canthomas indicates that this oncogene is not sufficient
to induce a frank malignant phenotype.
Comparison between H-ras
Activation in Human Benign and
Malignant Tumors of the Skin
The data presented above show that benign and self-
regressingtumors induced inrabbits with DMBA treat-
ment contain an activated H-ras oncogene. To find out
ifthe animalmodel wasreflectingthe scenario occurring
in humans, as well as to understand the specific role of
ras activation in the early stages oftumorigenesis, we
studied the frequency of H-ras mutations in keratoa-
canthomas and squamous cell carcinomas, two types of
tumors with clearly different biological behaviors.
The analysis to determine the presence of activated
ras genes in those tumors required the use of a sub-
stantial number of samples available only in the form
offormalin-fixed, paraffin-embedded tissue. It has been
previously shown that by PCR amplification, this ma-
terial can be screened for the presence of viral se-
quences (38) or ras mutations (39). The first and second
exons of the H-ras gene were amplified in vitro from
50 samples ofkeratoacanthomas and 50 samples ofsqua-
mous cell carcinomas using primers that have been de-
scribed elsewhere (9). One-tenth of the amplification
reaction mixture from each tumor as well as normal
control DNA was slot-blotted onto a nylon membrane
and hybridized with amixture ofoligonucleotide probes
specific for any mutation occurring in either the 12th or
the 61st codon ofH-ras. As amplification from formalin-
fixed and paraffin-embedded tissues is uneven, we
measured the signal produced when the slot blot is hy-
bridized with a probe that gives equal signals with the
normal and mutated H-ras alleles (data not shown). A
second slot blot was then preparerd, correcting for dif-
ferences in PCR amplificaton and hybridized with the
oligonucleotide probes specific for mutations in codon
12 and 61.
The results are shown in Table 2. Four mutations in
codon 12 and 10 mutations in codon 61 were identified
in keratoacanthomas, representing an incidence of30%
ofH-ras mutations among the benign tumors analyzed.
Three mutations in codon 12 and 3 in codon 61 were
identified in squamous cell carcinomas, representing a
significantly lower incidence (13%) of H-ras mutations
in these malignant skin tumors.
To validate further the data obtained in the PCR-
oligonucleotide hybridization analysis, we sequenced
some of the DNA fragments amplified from paraffin
blocks, although the use of the same filter for the dif-
ferent probes is in itself a demonstration of the selec-
tivity of washing conditions used. The nucleotide se-
quences oftheregion around codon 12 ofDNAamplified
from normal skin, from a freshly obtained keratoacan-
thoma, and from a paraffin-embedded tumor are shown
in Figure 4.
Discussion
The experiments presented in the skin tumors are an
indication of the usefulness of model systems to study
human disease. It is important to note that activation
of H-ras in this system seems to be an early event, as
it can be detected in benign tumors. In this particular
model system ofrabbit keratoacanthomas, not only the
activated oncogene is present in the benign growth, but
it seems to be unable to carry the tumors forward to-
ward malignant phenotype. This regressing behavior of
the keratacanthomas seems to be independent of an
inmunological reaction in both rabbits (40) and humans
(41). On the contrary, the regression seems to be pre-
ceded by an intense process ofdifferentiation that pro-
duces a marked keratinization that results in the for-
mation of a keratin plug that eventually falls off when
the regression is almost completed.
This observation, togetherwith the results presented
here in humans, where squamous cell carcinomas have
a significantly lower frequency ofH-ras activation than
keratoacanthomas, is consistent with the notion that H-
ras might be playing a role in differentiation during the
regressingphase ofthis tumor. This would explain why
H-ras is less frequentin squamous cell carcinomas since
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Table 2. Comparison between activation in codons 12 and 61 of the H-ras gene from human skin tumors.
Number of mutations
Codon Type of mutation Keratoacanthoma Squamous cell carcinoma
Cys (TGC) 2 2
H-ras codon 12 Ser (AGC) 2 0
Asp (GAC) 1 1
Lys (AAG) 1 0
H-ras codon 61 Arg (CGG) 1 0
Leu (CTG) 9 3




FIGURE 4. Direct sequence ofamplified H-ras first exon from human
keratoacanthomas. Region around codon 12 from normal skin (a),
freshly obtained tumor (b), and paraffin-embedded tissue (c) is
shown. The antisense primer used for the in vitro amplification
was the sequencing primer. Arrows indicate bands corresponding
to mutated base pairs.
its presence might be a deterrent to progression and
therefore selected against during malignantconversion.
The induction ofdifferentiation by ras oncogenes has
been previously reported by several groups including
ours in the PC12 system, where the introduction of a
ras oncogene or its product triggers neuronal differ-
entiation mimicking the action of nerve growth factor
(42-44). These observations would indicate that these
genes can play a complex role in the biology ofthe cell,
and depending on the system or the particular condi-
tions of the tissue, they could induce proliferation or
differentiation.
Another interesting result from these studies is the
pattern of H-ras mutation in rabbit and humans. In
rabbits the onlymutationessentiallydetected isthe A:T
to T:A transversion in the second position of codon 61
that changes glutamine to leucine. This is the mutation
previously reported in murine skin tumors induced by
DMBA (4,36), and therefore this seems to be an specific
target for DMBA that can be conserved through dif-
ferent species. When the mutations in human keratoa-
canthomas are analyzed, the results indicate that al-
though several othermutations are found, still the most
prevalent lesion is that detected in rabbits. This sug-
gests two possible explanations. On one hand, it could
be interpreted as an indication that the unknown agent
responsible for triggering human keratoacanthomas
might have a chemical action similar to DMBA. Alter-
natively, and more likely, the leucine substitution in
position 61 ofH-ras might have higher potential in skin
to induce proliferation, at least in the initial phases of
keratoacanthoma development.
From the technical side, it is important to note that
mutation studies can be successfully undertaken with
minimal archival material. Not only can the DNA con-
tained inone5-pumslicebeamplifiedbyPCRandstudied
by oligonucleotide mismatch hybridization, but also we
show that the material can often be good enough for
sequencing, an evenmore accurate determination ofthe
primary structure of the gene of interest. This allows
a comparison between the intensity ofthe bands forthe
bases representing the mutated and the normal se-
quence, providing anindication ofthe proportionofcells
in the tumor with a mutated oncogene.
The combination of PCR amplification and DNA se-
quencing was also the key to identify the new 146 mu-
tation found in one ofthe neutron-induced thymic lym-
phomas, where the correlation between the biological
assay (nude mouse tumorigenesis) and the molecular
findings (mismatch hybridization and sequence) was
clearly apparent.
The common thread linking the studies presented in
this paper is the frequent activation of ras oncogenes
in benign and malignant tumors, not only in experi-
mental systems ofcarcinogenesis, but in the human tu-
mors for which the animal.systems serve as models.
Additionally, the activation of the ras oncogene in
benign and self-regressingtumors and the factthat only
a fraction of malignant tumors contain activated ras
indicate that other events are necessary to fully com-
plete the progression to malignancy.
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